- ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
This study looks at a new medicine called TCD601 (siplizumab) for people who have recently had a kidney transplant. It compares TCD601 to a standard treatment to see if it's safe and how well it helps prevent the body from rejecting the new kidney.
Sweden · Spain · Austria - authorisedTherapeutic confirmatory (Phase III)
PREDONATION KIDNEY RESERVE: IMPACT IN THE EVOLUTION OF DONOR AND RECIPIENT RENAL FUNCTION IN A RENAL TRANSPLANTATION PROGRAMME OF LIVING DONOR
This study looks at how well kidneys work before and after a living kidney donation. Researchers want to see if a special solution helps protect the donated kidney and how this affects both the donor and the person receiving the kidney.
Spain